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Update
The clinical benefit of a new genomic instrument, the 70-gene signature
for breast cancer patients, is being evaluated in a randomised clinical
trial. The early, controlled implementation process is supported by a
Constructive Technology Assessment to help decision-making in an
uncertain time of development. 
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ment [2]. In 2002, researchers at the
Netherlands Cancer Institute (NKI,
Amsterdam, the Netherlands) identified a
70-gene prognosis signature (Mamma-
PrintTM), using microarray analysis for
lymph node-negative breast cancer patients
[3]. Using the 70-gene signature, the selec-
tion of patients that will benefit most from
adjuvant systemic treatment could be more
accurate. The signature has been validated
in three independent retrospective patient
series [4-6]. A prospective feasibility study,
the MicroarRAy PrognoSTics in Breast
CanER (RASTER)-study was started in
2004 [7]. 
Coverage decisions regarding new tech-
nologies often have to be made at a time
when the data on the most relevant vari-
ables and adequate comparisons are not
yet available from high-quality studies.
Especially when the promising new tech-
nology is in its early development phase
and certain stakeholders find reason to
speed up implementation in clinical prac-
tice, health policy challenges arise. 
Health Technology Assessment (HTA) is
widely adopted to help manage the intro-
duction and appropriate use of new tech-
nologies [8]. However, a HTA generally
starts after the technology is stabilised
and proved to be valid in clinical trials.
During this time many changes in avail-
able treatments can occur, which results
in a HTA subsequently answering, at
least partly, outdated questions [9].
Genomic knowledge leads to the intro-
duction of new and increasingly person-
alised diagnostics and treatments, which
lead to even more complex evaluation
designs when following common and
accepted assessment practices. Thus, it
T
reatment for patients with
cancer has shifted from
administering broadly toxic
drugs towards fine-tuning
of therapies that are target-
ed to the personal characteristics of spe-
cific tumours. An example of this develop-
ment is the possibility to base the decision
of adjuvant systemic therapy for breast can-
cer on the results of a genomic prognostic
profile. The majority of early stage breast
cancer patients, particular with lymph node-
negative disease (60-70%), have a fairly
good 10-year overall survival with locore-
gional treatment alone, with only 30-40%
developing distant metastasis [1].
Nevertheless, according to current guide-
lines, most lymph node negative breast can-
cer patients are offered chemotherapy, caus-
ing an important percentage of over-treat-
would take at least 8-10 years to bring
the 70-gene signature into clinical prac-
tice, via the usual path of prospective trials.
For these reasons, we chose to carry out
a controlled introduction of the 70-
gene signature, supported with a com-
prehensive technology assessment,
which takes technology dynamics into
account, and decided to perform a
Constructive Technology Assessment
(CTA). CTA is based on the idea that
during the course of technology devel-
opment, choices are constantly being
made about the form, the function, and
the use of that technology [10]. This
assessment method is a possible answer
to the (economic) evaluation challenges
that new genomic technologies pose. 
MINDACT-trial
After the results of the controlled intro-
duction trial were known [7], in the
Netherlands a discussion was started
whether Coverage with Evidence
Development (CED) would be appropri-
ate. CED represents a specific approach to
coverage for promising technologies for
which the evidence is uncertain yet [8].
Parallel additional prospective evidence
on the validity of the prognostic use was
needed for which the MINDACT-trial
Microarray In Node-negative Disease
may Avoid ChemoTherapy) was organ-
ised. The MINDACT-trial evaluates
whether use of the 70-gene signature is
associated with clinical benefit. The ran-
domised controlled design allows a
defined group of patients (age 18-70, node
negative, operable breast cancer) to have
their treatment determined on the basis of
either the 70-gene signature or standard
practice guidelines. Patients with discor-
dant risk profiles will be randomised to
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chemotherapy treatment according to
either the clinicopathological criteria
(using the Adjuvant! Online software
[11]) or according to the 70-gene signa-
ture [12]. The trial plans to prospectively
recruit 6,000 patients. A follow up of at
least ten years will be required before the
results are available [13]. At this time, the
trial is currently running in eight
European countries. 
Constructive Technology
Assessment
The CTA is related to a Health
Technology Assessment (HTA), which
predominantly implies a cost-effective-
ness analysis (CEA) or economic evalua-
tion. CTA also takes technology dynamics
into account and has developed from just
assessing the impact of a new technology
to the analysis of design, development,
implementation and interaction of that
new technology with its environment.
Only a few publications are available
describing the application of CTA in
health care [9, 14, 15]. The aspects studied
in this CTA on the 70-gene signature so
far were: patient-related aspects (under-
standing of the 70-gene signature and psy-
chological impact), organisational effi-
ciency (logistics and team functioning)
and diffusion scenarios [15]. Partially
based on these data, a dynamic economic
evaluation will be conducted.
Scenarios
Scenario drafting can be used as a tool in
forecasting of new, still dynamic tech-
nologies and is commonly applied in
industry to anticipate future develop-
ment and diffusion of their products.
Scenarios can be used to monitor the
implementation process through the var-
ious diffusion phases and can support
and identify the need for evaluation or
even interfere through formal decision
making. In the case of the 70-gene sig-
nature, the scenarios were written using
the timeline of diffusion phases as
described by Rogers’ theory, 2003 [16],
see Figure 1. These phases reflect the
degree of spreading throughout the
(medical) society. In the innovation
phase, the prognosis signature technique
is developed and the first organisations
adopt (introduce) the technology in their
daily practice. The first scenario was
written before the prognosis signature
was introduced in the Netherlands (mid-
2004). The early adoption phase
describes the implementation in 10-15
hospitals. The second, revised scenario
was drafted based on the first experi-
ences in the feasibility study (RASTER)
in the Netherlands (mid-2005). The
early majority phase describes the
implementation in a gradually increasing
number of hospitals and is ongoing. The
most recent scenario written at the
beginning of the MINDACT trial (mid-
2008), incorporating ten alternatives,
was first checked by genomic experts
and breast cancer specialists, and vali-
dated in a recent workshop among 50
European breast cancer experts.
Dynamic Economic Evaluation
The scenarios drafted on the subsequent
phases of diffusion describe possible
“future worlds” of the use of the 70-gene
signature. Probabilistic decision model-
ling will be used to estimate the cost-
effectiveness of the 70-gene signature
in these worlds, which may alter as
time progresses and more information
becomes available. The various alterna-
tives, barriers or facilitators that influ-
ence the diffusion of the 70-gene signa-
ture will be incorporated into the model
as stochastic parameters. Parameters
will be updated as soon as new infor-
mation becomes available. At each
moment in time, the decision to adopt
or reject the new technology based on
existing knowledge, and the decision
whether more evidence is required can be
informed by the results of the model [17].
Cost-effectiveness Acceptability Curves
(CEACs) will reflect the degree of deci-
sion uncertainty and Value of Information
Analyses (VOI) implies whether addition-
al evidence to further inform the decision
is worth gathering, and what kind of infor-
mation is of the greatest value [18]. VOI is
the amount a decision maker would be
willing to pay for information prior to
making a decision. 
Conclusions
Establishing the cost-effectiveness of
genetic targeting of cancer therapies is
increasingly desirable in an early stage
when “traditional” prospective ran-
domised controlled data are not within
reach. In the MINDACT-trial that would
take another 8-10 years and future tech-
Figure 1: Adoption curve of Rogers’, applied to the case of the 70-gene signature 
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Update
The National Institute for Health and Clinical Excellence (NICE), issues mandatory guidance on the use
of health technologies within the UK National Health Service. This paper reviews a study involving a
model developed to identify which factors influence NICE’s technology appraisal decisions. 
What makes NICE tick?
Isaac AO Odeyemi, MBA, PhD
T
he National Institute for
Clinical Excellence (NICE),
subsequently renamed the
National Institute for
Health and Clinical Excel-
lence, was established by the UK gov-
ernment in 1999 as an independent
organisation to provide guidance to the
National Health Service (NHS) in
England and Wales on the clinical and
cost-effectiveness of new and existing
clinical interventions. Since January
2002, NHS organisations in England and
Wales have been required to provide
mandatory funding for medicines and
treatments recommended by NICE in its
technology appraisals guidance [1].
NICE’s technology appraisal decisions
are based on a range of factors, includ-
ing the strength of clinical-effectiveness
evidence, cost-effectiveness, the avail-
ability of alternative treatments, and the
potential for long-term benefits to the
NHS from innovation [2, 3]. However,
the decision-making criteria other than
cost-effectiveness have not been codi-
fied by NICE and remain enigmatic [4]. 
nologies with further personalised dif-
ferentiation might even lead to conclu-
sions that more qualitative trials will be
conducted. However, the challenge is
still to inform policy makers about pos-
sible advantages or disadvantages and,
ultimately, to aid a decision on usage
and coverage. A CTA evaluates a new
technology in an early and unstable
stage of development. Scenarios help to
monitor the controlled introduction
process and can even assist in anticipat-
ing on future developments. Dynamic
economic evaluation can support the
decision making, by taking the several
scenarios per diffusion phase into
account in a decision model. We expect
that these methods will prove valuable in
combination with more “traditional”
cost-effectiveness analysis approaches.
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